



SurModics' New Low Friction, Low Particulate Device Coatings Introduced

February 11, 2013

SurModics Serene™ hydrophilic coatings address unmet need for lubricious, low particulate medical device coatings

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 11, 2013-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics [Serene™ lubricious coating](#) for endovascular medical devices. *Serene* coatings are a breakthrough technology that delivers lubricity and durability while significantly reducing particulates. They are optimized for a wide range of catheter substrates and are used on FDA-cleared coronary and peripheral devices. The new coating is being introduced at the MD&M West meeting currently taking place in Anaheim, Calif.

"The *Serene* coating platform successfully addresses medical device manufacturers' interest in a high-performance lubricious coating that also yields the lowest amount of particulates," says Charlie Olson, senior vice president and general manager of SurModics' Medical Device business.

Particulate generation during endovascular procedures is an area of interest for regulators. Several factors can contribute to particulate generation: device materials and design, device coatings, clinical technique, and the type of procedure. In recent years, manufacturers of minimally invasive medical devices have received more characterization requests from regulatory agencies seeking test results and justifications for particulate levels associated with their coated devices.

While medical device manufacturers cannot control all the variables that may result in particulate generation, SurModics *Serene* coatings give them the option of a lower particulate coating platform that optimizes both lubricity and durability.

"This next-generation coating is the culmination of several years of development work," says Gary Maharaj, president and chief executive officer. "As a market leader in coatings, we will continue to create innovative products that help advance our customers' coronary, peripheral, neuro, and structural heart devices."

About SurModics, Inc.

SurModics' mission is to exceed our customers' expectations and enhance patients' well-being by providing the world's foremost, innovative surface modification technologies and *in vitro* diagnostic chemical components. SurModics partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics, and components for *in vitro* diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minn. For more information, visit www.surmodics.com. The content of SurModics' website is not part of this press release or part of any filings that the Company makes with the SEC.

Source: SurModics, Inc.

SurModics, Inc.

Tim Arens, 952-500-7000

Vice President, Finance and Interim Chief Financial Officer